194 related articles for article (PubMed ID: 11291041)
21. Sensitization of cancer cells to interleukin 13-pseudomonas exotoxin-induced cell death by gene transfer of interleukin 13 receptor alpha chain.
Kawakami K; Joshi BH; Puri RK
Hum Gene Ther; 2000 Sep; 11(13):1829-35. PubMed ID: 10986556
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-13 receptors on human prostate carcinoma cell lines represent a novel target for a chimeric protein composed of IL-13 and a mutated form of Pseudomonas exotoxin.
Maini A; Hillman G; Haas GP; Wang CY; Montecillo E; Hamzavi F; Pontes JE; Leland P; Pastan I; Debinski W; Puri RK
J Urol; 1997 Sep; 158(3 Pt 1):948-53. PubMed ID: 9258124
[TBL] [Abstract][Full Text] [Related]
23. IL-13 fusion cytotoxin ameliorates chronic fungal-induced allergic airway disease in mice.
Blease K; Jakubzick C; Schuh JM; Joshi BH; Puri RK; Hogaboam CM
J Immunol; 2001 Dec; 167(11):6583-92. PubMed ID: 11714828
[TBL] [Abstract][Full Text] [Related]
24. Combined effects of radiation and interleukin-13 receptor-targeted cytotoxin on glioblastoma cell lines.
Kawakami K; Kawakami M; Liu Q; Puri RK
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):230-7. PubMed ID: 16111594
[TBL] [Abstract][Full Text] [Related]
25. Tumor regression mechanisms by IL-13 receptor-targeted cancer therapy involve apoptotic pathways.
Kawakami M; Kawakami K; Puri RK
Int J Cancer; 2003 Jan; 103(1):45-52. PubMed ID: 12455052
[TBL] [Abstract][Full Text] [Related]
26. Pancreatic cancer cells express interleukin-13 and -4 receptors, and their growth is inhibited by Pseudomonas exotoxin coupled to interleukin-13 and -4.
Kornmann M; Kleeff J; Debinski W; Korc M
Anticancer Res; 1999; 19(1A):125-31. PubMed ID: 10226533
[TBL] [Abstract][Full Text] [Related]
27. Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model.
Kawakami K; Kawakami M; Kioi M; Husain SR; Puri RK
J Neurosurg; 2004 Dec; 101(6):1004-11. PubMed ID: 15597761
[TBL] [Abstract][Full Text] [Related]
28. Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL-13Ralpha2-expressing contralateral tumors.
Kawakami K; Terabe M; Kioi M; Berzofsky JA; Puri RK
Clin Cancer Res; 2006 Aug; 12(15):4678-86. PubMed ID: 16899618
[TBL] [Abstract][Full Text] [Related]
29. Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein.
Husain SR; Obiri NI; Gill P; Zheng T; Pastan I; Debinski W; Puri RK
Clin Cancer Res; 1997 Feb; 3(2):151-6. PubMed ID: 9815666
[TBL] [Abstract][Full Text] [Related]
30. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4.
Debinski W; Obiri NI; Pastan I; Puri RK
J Biol Chem; 1995 Jul; 270(28):16775-80. PubMed ID: 7622490
[TBL] [Abstract][Full Text] [Related]
31. Cytotoxins directed at interleukin-4 receptors as therapy for human brain tumors.
Puri RK
Methods Mol Biol; 2001; 166():155-76. PubMed ID: 11217365
[No Abstract] [Full Text] [Related]
32. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma.
Puri RK; Hoon DS; Leland P; Snoy P; Rand RW; Pastan I; Kreitman RJ
Cancer Res; 1996 Dec; 56(24):5631-7. PubMed ID: 8971168
[TBL] [Abstract][Full Text] [Related]
33. Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy.
Shimamura T; Fujisawa T; Husain SR; Joshi B; Puri RK
Clin Cancer Res; 2010 Jan; 16(2):577-86. PubMed ID: 20068108
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic efficacy of Cintredekin Besudotox (IL13-PE38QQR) in murine lung fibrosis is unaffected by immunity to Pseudomonas aeruginosa exotoxin A.
Rosada RS; Moreira AP; Frantz FG; Puri RK; Rahman A; Standiford TJ; Zárate-Bladés CR; Silva CL; Hogaboam CM
PLoS One; 2010 Jan; 5(1):e8721. PubMed ID: 20090941
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts.
Beseth BD; Cameron RB; Leland P; You L; Varricchio F; Kreitman RJ; Maki RA; Jablons DM; Husain SR; Puri RK
Ann Thorac Surg; 2004 Aug; 78(2):436-43; discussion 436-43. PubMed ID: 15276492
[TBL] [Abstract][Full Text] [Related]
36. Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma.
Kreitman RJ; Puri RK; Pastan I
Cancer Res; 1995 Aug; 55(15):3357-63. PubMed ID: 7614471
[TBL] [Abstract][Full Text] [Related]
37. A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature.
Tsai AK; Oh S; Chen H; Shu Y; Ohlfest JR; Vallera DA
J Neurooncol; 2011 Jun; 103(2):255-66. PubMed ID: 20830604
[TBL] [Abstract][Full Text] [Related]
38. Identification of distinct roles for a dileucine and a tyrosine internalization motif in the interleukin (IL)-13 binding component IL-13 receptor alpha 2 chain.
Kawakami K; Takeshita F; Puri RK
J Biol Chem; 2001 Jul; 276(27):25114-20. PubMed ID: 11352909
[TBL] [Abstract][Full Text] [Related]
39. Interleukin-4 receptors expressed on tumor cells may serve as a target for anticancer therapy using chimeric Pseudomonas exotoxin.
Debinski W; Puri RK; Pastan I
Int J Cancer; 1994 Sep; 58(5):744-8. PubMed ID: 8077061
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model.
Husain SR; Kreitman RJ; Pastan I; Puri RK
Nat Med; 1999 Jul; 5(7):817-22. PubMed ID: 10395328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
